GHK-Cu
A copper-binding peptide used in cosmetic and wound-healing discussions, especially around skin appearance and tissue signaling.
Also referenced as: Copper Tripeptide-1
Also appears in: Tissue repair
What has the price actually done?
Daily, exact-comparability offers. Discounts use the terms known on each historical date.
How this history is calculated
Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.
Let the market come to you.
Watch the best market price or one vendor. Get one email when GHK-Cu crosses your target, drops, or sets a new tracked low—without daily noise.
This name primarily lives in the research market and should not be read like an approved pharmaceutical product.
Primary research area: Dermal. Also surfaces under Tissue repair for browsing and discovery.
Copper Tripeptide-1
FDA label signal · 2 trials · 89 PubMed results
GHK-Cu has name-matched human trials with published or reported controlled evidence, but is not FDA-approved. The research is real and ongoing — treat findings as developing rather than settled.
GHK-Cu has 2 name-matched clinical trials (highest phase: Phase 2) and 89 PubMed-indexed publications and is not FDA-approved. Human trials are registered but none have posted results yet.
Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.
Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-09-08 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →
What GHK-Cu is
GHK-Cu is a copper-binding tripeptide often discussed in skin-care, hair-care, and wound-signaling contexts. It is one of the better-known examples of how the peptide category extends beyond injectables and metabolic drugs into cosmetic and topical discussions.
Why it matters
On a peptide site, GHK-Cu helps broaden the picture. Not every peptide profile is about body composition or medicalized GLP-1 use. Some peptides are tracked because they show up in dermal, regenerative, or cosmetic product discussions.
Regulatory context
GHK-Cu is not an FDA-approved peptide drug indication in the sense that semaglutide or tesamorelin are. Readers should distinguish between cosmetic ingredient use, research discussion, and regulated therapeutic claims.
Practical reading note
When GHK-Cu is marketed aggressively, the main issue is usually not whether the peptide exists, but whether the seller is overstating what cosmetic or regenerative signaling research can prove.